20 reports of this reaction
2.2% of all ISOPROTERENOL HYDROCHLORIDE reports
#7 most reported adverse reaction
TOXIC EPIDERMAL NECROLYSIS is the #7 most commonly reported adverse reaction for ISOPROTERENOL HYDROCHLORIDE, manufactured by Cipla USA Inc.. There are 20 FDA adverse event reports linking ISOPROTERENOL HYDROCHLORIDE to TOXIC EPIDERMAL NECROLYSIS. This represents approximately 2.2% of all 894 adverse event reports for this drug.
Patients taking ISOPROTERENOL HYDROCHLORIDE who experience toxic epidermal necrolysis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
TOXIC EPIDERMAL NECROLYSIS is a less commonly reported adverse event for ISOPROTERENOL HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to toxic epidermal necrolysis, the following adverse reactions have been reported for ISOPROTERENOL HYDROCHLORIDE:
TOXIC EPIDERMAL NECROLYSIS has been reported as an adverse event in 20 FDA reports for ISOPROTERENOL HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
TOXIC EPIDERMAL NECROLYSIS accounts for approximately 2.2% of all adverse event reports for ISOPROTERENOL HYDROCHLORIDE, making it a notable side effect.
If you experience toxic epidermal necrolysis while taking ISOPROTERENOL HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.